Jennifer Taylor-Cousar
Concepts (353)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 134 | 2026 | 1163 | 23.340 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 81 | 2026 | 373 | 15.620 |
Why?
| | Quinolones | 42 | 2026 | 204 | 9.650 |
Why?
| | Aminophenols | 53 | 2026 | 203 | 9.450 |
Why?
| | Benzodioxoles | 38 | 2026 | 161 | 7.070 |
Why?
| | Chloride Channel Agonists | 34 | 2026 | 110 | 5.600 |
Why?
| | Indoles | 31 | 2026 | 507 | 4.460 |
Why?
| | Sinusitis | 12 | 2025 | 227 | 3.690 |
Why?
| | Pyridines | 25 | 2026 | 609 | 3.010 |
Why?
| | Pyrrolidines | 22 | 2026 | 125 | 2.920 |
Why?
| | Rhinitis | 10 | 2025 | 169 | 2.880 |
Why?
| | Pyrazoles | 27 | 2026 | 517 | 2.760 |
Why?
| | Drug Combinations | 30 | 2026 | 396 | 2.280 |
Why?
| | Olfaction Disorders | 8 | 2025 | 70 | 2.200 |
Why?
| | Aminopyridines | 7 | 2026 | 129 | 2.010 |
Why?
| | Pregnancy Complications | 7 | 2026 | 603 | 1.840 |
Why?
| | Mutation | 34 | 2024 | 4090 | 1.830 |
Why?
| | Membrane Transport Modulators | 3 | 2020 | 7 | 1.760 |
Why?
| | Fetal Therapies | 2 | 2026 | 47 | 1.750 |
Why?
| | Pongo pygmaeus | 3 | 2024 | 7 | 1.730 |
Why?
| | Ape Diseases | 3 | 2024 | 7 | 1.500 |
Why?
| | Reproductive Health | 9 | 2024 | 91 | 1.320 |
Why?
| | Humans | 143 | 2026 | 145763 | 1.270 |
Why?
| | Azithromycin | 7 | 2021 | 101 | 1.230 |
Why?
| | Pregnancy | 23 | 2026 | 7215 | 1.210 |
Why?
| | Pregnancy Outcome | 7 | 2026 | 504 | 1.210 |
Why?
| | Quality of Life | 18 | 2026 | 3210 | 1.200 |
Why?
| | Adult | 71 | 2026 | 40872 | 1.100 |
Why?
| | Respiratory System Agents | 2 | 2020 | 22 | 1.060 |
Why?
| | Parents | 5 | 2024 | 1407 | 1.050 |
Why?
| | Sexual Health | 6 | 2025 | 68 | 1.050 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2025 | 47 | 1.040 |
Why?
| | Quinolines | 10 | 2026 | 190 | 1.030 |
Why?
| | Female | 84 | 2026 | 79035 | 1.010 |
Why?
| | Paranasal Sinuses | 5 | 2024 | 81 | 0.920 |
Why?
| | Sweat | 10 | 2026 | 51 | 0.850 |
Why?
| | Pseudomonas Infections | 9 | 2024 | 230 | 0.840 |
Why?
| | Chronic Disease | 15 | 2026 | 1812 | 0.840 |
Why?
| | Drug Approval | 3 | 2024 | 93 | 0.830 |
Why?
| | Fetal Diseases | 1 | 2026 | 194 | 0.810 |
Why?
| | Respiratory Mucosa | 2 | 2025 | 322 | 0.810 |
Why?
| | Pregnancy Rate | 3 | 2021 | 81 | 0.810 |
Why?
| | Pongo | 2 | 2021 | 7 | 0.800 |
Why?
| | Anti-Bacterial Agents | 12 | 2024 | 1925 | 0.790 |
Why?
| | Genetic Therapy | 5 | 2026 | 316 | 0.770 |
Why?
| | Treatment Outcome | 26 | 2026 | 11793 | 0.760 |
Why?
| | Prospective Studies | 18 | 2026 | 8075 | 0.710 |
Why?
| | Male | 64 | 2026 | 73003 | 0.690 |
Why?
| | Lung | 10 | 2026 | 4116 | 0.690 |
Why?
| | Chlorides | 9 | 2026 | 138 | 0.680 |
Why?
| | Aerosols | 2 | 2026 | 145 | 0.670 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1101 | 0.660 |
Why?
| | Lung Transplantation | 1 | 2024 | 332 | 0.660 |
Why?
| | Glucose Intolerance | 2 | 2025 | 142 | 0.650 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.650 |
Why?
| | Sputum | 6 | 2026 | 302 | 0.630 |
Why?
| | Young Adult | 31 | 2026 | 14251 | 0.630 |
Why?
| | Compassionate Use Trials | 1 | 2019 | 7 | 0.610 |
Why?
| | Smell | 4 | 2025 | 126 | 0.600 |
Why?
| | Transcriptome | 1 | 2025 | 1042 | 0.580 |
Why?
| | Fertility | 3 | 2025 | 174 | 0.570 |
Why?
| | Precision Medicine | 2 | 2021 | 461 | 0.570 |
Why?
| | Glucose Tolerance Test | 3 | 2026 | 361 | 0.550 |
Why?
| | Pseudomonas aeruginosa | 9 | 2022 | 395 | 0.550 |
Why?
| | Breast Feeding | 3 | 2025 | 447 | 0.550 |
Why?
| | Forced Expiratory Volume | 11 | 2023 | 450 | 0.540 |
Why?
| | Adolescent | 32 | 2026 | 22573 | 0.520 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 261 | 0.520 |
Why?
| | Drug Monitoring | 6 | 2020 | 401 | 0.510 |
Why?
| | Contraceptives, Oral, Hormonal | 3 | 2026 | 30 | 0.510 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 28 | 0.500 |
Why?
| | Child | 24 | 2025 | 22739 | 0.490 |
Why?
| | Rifampin | 1 | 2017 | 79 | 0.490 |
Why?
| | Leukocyte Elastase | 2 | 2026 | 75 | 0.480 |
Why?
| | Pongo abelii | 1 | 2016 | 1 | 0.480 |
Why?
| | Biomedical Research | 3 | 2024 | 719 | 0.470 |
Why?
| | Surveys and Questionnaires | 12 | 2026 | 6085 | 0.450 |
Why?
| | Sildenafil Citrate | 2 | 2014 | 60 | 0.440 |
Why?
| | Bronchiectasis | 1 | 2016 | 115 | 0.420 |
Why?
| | Tobramycin | 5 | 2019 | 63 | 0.420 |
Why?
| | Infertility, Male | 2 | 2025 | 80 | 0.410 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2020 | 655 | 0.400 |
Why?
| | Double-Blind Method | 11 | 2026 | 2064 | 0.400 |
Why?
| | Genotype | 9 | 2026 | 1857 | 0.370 |
Why?
| | Respiratory Function Tests | 6 | 2025 | 544 | 0.360 |
Why?
| | Lactation | 3 | 2022 | 193 | 0.350 |
Why?
| | Contraception Behavior | 2 | 2025 | 108 | 0.340 |
Why?
| | Homozygote | 4 | 2021 | 199 | 0.330 |
Why?
| | Contraception | 2 | 2025 | 170 | 0.320 |
Why?
| | Drug Interactions | 4 | 2020 | 405 | 0.300 |
Why?
| | International Cooperation | 2 | 2020 | 197 | 0.300 |
Why?
| | Alleles | 8 | 2025 | 896 | 0.290 |
Why?
| | Hypoventilation | 1 | 2009 | 17 | 0.290 |
Why?
| | Respiratory Muscles | 1 | 2009 | 37 | 0.290 |
Why?
| | Animals | 13 | 2026 | 38097 | 0.290 |
Why?
| | Blood Glucose | 3 | 2025 | 2344 | 0.280 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 58 | 0.270 |
Why?
| | Parenting | 2 | 2023 | 319 | 0.270 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1062 | 0.270 |
Why?
| | Pyrroles | 2 | 2026 | 220 | 0.270 |
Why?
| | Tomography, X-Ray Computed | 4 | 2022 | 2770 | 0.250 |
Why?
| | Asthma | 3 | 2024 | 1797 | 0.250 |
Why?
| | Needs Assessment | 2 | 2020 | 403 | 0.250 |
Why?
| | Middle Aged | 22 | 2026 | 36302 | 0.250 |
Why?
| | Quinuclidines | 1 | 2026 | 11 | 0.240 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 615 | 0.230 |
Why?
| | Sexual Behavior | 3 | 2025 | 495 | 0.230 |
Why?
| | United States | 11 | 2025 | 16123 | 0.230 |
Why?
| | Dependovirus | 1 | 2026 | 78 | 0.230 |
Why?
| | Phenylpropionates | 1 | 2025 | 27 | 0.230 |
Why?
| | Infant, Newborn | 5 | 2026 | 6464 | 0.230 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 134 | 0.220 |
Why?
| | Airway Remodeling | 1 | 2025 | 63 | 0.220 |
Why?
| | Off-Label Use | 1 | 2025 | 51 | 0.220 |
Why?
| | Cough | 1 | 2026 | 124 | 0.220 |
Why?
| | Oligonucleotides, Antisense | 1 | 2025 | 120 | 0.220 |
Why?
| | Biomarkers | 6 | 2026 | 4302 | 0.210 |
Why?
| | Organoids | 1 | 2026 | 144 | 0.200 |
Why?
| | Fertility Preservation | 1 | 2024 | 55 | 0.200 |
Why?
| | Minimal Clinically Important Difference | 1 | 2023 | 31 | 0.200 |
Why?
| | Food Preferences | 1 | 2025 | 126 | 0.200 |
Why?
| | Liver Cirrhosis | 1 | 2026 | 287 | 0.200 |
Why?
| | Orphan Drug Production | 1 | 2023 | 5 | 0.200 |
Why?
| | Pregnancy, Unplanned | 2 | 2023 | 48 | 0.200 |
Why?
| | C-Reactive Protein | 2 | 2018 | 423 | 0.200 |
Why?
| | Sexually Transmitted Diseases | 1 | 2025 | 168 | 0.190 |
Why?
| | Patient Selection | 2 | 2019 | 739 | 0.190 |
Why?
| | Intestines | 1 | 2026 | 354 | 0.190 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 175 | 0.190 |
Why?
| | Ion Transport | 2 | 2021 | 62 | 0.190 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 119 | 0.190 |
Why?
| | Neonatal Screening | 1 | 2024 | 179 | 0.180 |
Why?
| | Body Height | 1 | 2023 | 203 | 0.180 |
Why?
| | Puberty | 1 | 2023 | 137 | 0.180 |
Why?
| | Azabicyclo Compounds | 1 | 2021 | 7 | 0.180 |
Why?
| | Epoxide Hydrolases | 1 | 2021 | 13 | 0.170 |
Why?
| | Enzyme Activators | 1 | 2021 | 9 | 0.170 |
Why?
| | Inflammation | 3 | 2026 | 2883 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2028 | 0.170 |
Why?
| | Benzoates | 1 | 2021 | 51 | 0.170 |
Why?
| | RNA, Messenger | 3 | 2022 | 2805 | 0.170 |
Why?
| | Retrospective Studies | 11 | 2026 | 17325 | 0.170 |
Why?
| | Men's Health | 1 | 2020 | 6 | 0.170 |
Why?
| | Cyclopropanes | 3 | 2026 | 84 | 0.170 |
Why?
| | Endoscopy | 4 | 2024 | 317 | 0.160 |
Why?
| | Vascular Stiffness | 1 | 2026 | 487 | 0.160 |
Why?
| | Infertility | 1 | 2021 | 61 | 0.160 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 413 | 0.160 |
Why?
| | Women's Rights | 1 | 2020 | 4 | 0.160 |
Why?
| | Communicable Disease Control | 1 | 2020 | 86 | 0.160 |
Why?
| | Disease Progression | 5 | 2020 | 2865 | 0.160 |
Why?
| | Virulence Factors | 2 | 2014 | 175 | 0.150 |
Why?
| | Aztreonam | 2 | 2016 | 11 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 2 | 2025 | 883 | 0.150 |
Why?
| | Cataract | 1 | 2022 | 238 | 0.150 |
Why?
| | Colistin | 1 | 2019 | 10 | 0.150 |
Why?
| | Neutrophils | 3 | 2016 | 1125 | 0.150 |
Why?
| | Medication Therapy Management | 1 | 2020 | 72 | 0.150 |
Why?
| | Sexism | 1 | 2020 | 68 | 0.150 |
Why?
| | Pilot Projects | 3 | 2026 | 1897 | 0.150 |
Why?
| | Epithelial Cells | 3 | 2026 | 1134 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2025 | 1420 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5428 | 0.140 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 29 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.130 |
Why?
| | Health Status | 1 | 2023 | 835 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2933 | 0.130 |
Why?
| | Administration, Oral | 1 | 2020 | 867 | 0.130 |
Why?
| | Pyrimidines | 1 | 2021 | 530 | 0.130 |
Why?
| | Mental Health | 1 | 2024 | 796 | 0.130 |
Why?
| | Insulin Resistance | 1 | 2026 | 1244 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 498 | 0.130 |
Why?
| | HEK293 Cells | 1 | 2020 | 741 | 0.130 |
Why?
| | Pregnancy, High-Risk | 1 | 2017 | 13 | 0.130 |
Why?
| | Leukocytes | 1 | 2018 | 296 | 0.130 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 396 | 0.120 |
Why?
| | Biological Availability | 1 | 2017 | 145 | 0.120 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 67 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2967 | 0.120 |
Why?
| | Research | 1 | 2020 | 431 | 0.120 |
Why?
| | Risk Assessment | 3 | 2021 | 3752 | 0.120 |
Why?
| | Risk Factors | 5 | 2026 | 10917 | 0.120 |
Why?
| | Risk Adjustment | 1 | 2017 | 85 | 0.120 |
Why?
| | Prognosis | 2 | 2022 | 4329 | 0.120 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1777 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 251 | 0.120 |
Why?
| | Albuterol | 1 | 2016 | 76 | 0.110 |
Why?
| | Recovery of Function | 1 | 2020 | 716 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2017 | 175 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 484 | 0.110 |
Why?
| | Health Services Accessibility | 2 | 2024 | 1101 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2023 | 1197 | 0.110 |
Why?
| | Interferons | 1 | 2016 | 186 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2016 | 225 | 0.110 |
Why?
| | Bronchodilator Agents | 1 | 2016 | 187 | 0.110 |
Why?
| | Machine Learning | 1 | 2020 | 587 | 0.110 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 393 | 0.110 |
Why?
| | Child, Preschool | 3 | 2024 | 11868 | 0.110 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2014 | 40 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 42 | 0.100 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 410 | 0.100 |
Why?
| | Quorum Sensing | 1 | 2014 | 80 | 0.100 |
Why?
| | Exercise | 1 | 2026 | 2205 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2399 | 0.100 |
Why?
| | Body Mass Index | 2 | 2023 | 2447 | 0.100 |
Why?
| | Preconception Care | 2 | 2025 | 50 | 0.100 |
Why?
| | Administration, Inhalation | 3 | 2022 | 571 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 55 | 0.090 |
Why?
| | Neutrophil Activation | 1 | 2013 | 84 | 0.090 |
Why?
| | Condoms | 2 | 2025 | 102 | 0.090 |
Why?
| | Wound Infection | 1 | 2013 | 60 | 0.090 |
Why?
| | Registries | 4 | 2026 | 2410 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 101 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1662 | 0.090 |
Why?
| | Microbial Viability | 1 | 2011 | 83 | 0.080 |
Why?
| | Extracellular Space | 1 | 2011 | 117 | 0.080 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1043 | 0.080 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 701 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 574 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 220 | 0.080 |
Why?
| | Infant | 1 | 2024 | 10090 | 0.080 |
Why?
| | Survival Rate | 2 | 2018 | 2094 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5922 | 0.070 |
Why?
| | Sex Factors | 2 | 2026 | 2110 | 0.070 |
Why?
| | Blood Group Antigens | 1 | 2009 | 15 | 0.070 |
Why?
| | Incidence | 2 | 2026 | 2933 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2191 | 0.070 |
Why?
| | Aged | 5 | 2024 | 26215 | 0.070 |
Why?
| | Mucus | 1 | 2009 | 75 | 0.070 |
Why?
| | ADP Ribose Transferases | 1 | 2007 | 9 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | Furin | 1 | 2007 | 12 | 0.070 |
Why?
| | Mass Screening | 1 | 2016 | 1361 | 0.070 |
Why?
| | Inpatients | 1 | 2012 | 553 | 0.070 |
Why?
| | Burns | 1 | 2013 | 374 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 17 | 0.070 |
Why?
| | Cyclic GMP | 1 | 2007 | 90 | 0.060 |
Why?
| | Time Factors | 3 | 2024 | 7133 | 0.060 |
Why?
| | Bacterial Toxins | 1 | 2007 | 108 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2601 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 181 | 0.060 |
Why?
| | Phenotype | 1 | 2015 | 3170 | 0.060 |
Why?
| | Thiazolidines | 1 | 2026 | 13 | 0.060 |
Why?
| | Sulfones | 1 | 2007 | 127 | 0.060 |
Why?
| | Survivors | 1 | 2010 | 523 | 0.060 |
Why?
| | Oxadiazoles | 1 | 2026 | 37 | 0.060 |
Why?
| | Respiratory System | 1 | 2007 | 150 | 0.060 |
Why?
| | Transduction, Genetic | 1 | 2026 | 132 | 0.060 |
Why?
| | Rats | 2 | 2026 | 5585 | 0.060 |
Why?
| | Transgenes | 1 | 2026 | 190 | 0.060 |
Why?
| | Rats, Inbred F344 | 1 | 2026 | 268 | 0.060 |
Why?
| | Actigraphy | 1 | 2026 | 148 | 0.060 |
Why?
| | Quinoxalines | 1 | 2025 | 65 | 0.060 |
Why?
| | Pulse Wave Analysis | 1 | 2026 | 267 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2026 | 335 | 0.050 |
Why?
| | European Union | 1 | 2024 | 12 | 0.050 |
Why?
| | Piperazines | 1 | 2007 | 375 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 714 | 0.050 |
Why?
| | Reproductive Health Services | 1 | 2023 | 19 | 0.050 |
Why?
| | Standard of Care | 1 | 2024 | 81 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2139 | 0.050 |
Why?
| | Developing Countries | 1 | 2026 | 317 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.050 |
Why?
| | Nose | 1 | 2023 | 67 | 0.050 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2024 | 62 | 0.050 |
Why?
| | Cell Separation | 2 | 2016 | 306 | 0.050 |
Why?
| | Deoxyribonuclease I | 1 | 2022 | 41 | 0.050 |
Why?
| | Vasodilation | 1 | 2026 | 521 | 0.050 |
Why?
| | Saline Solution, Hypertonic | 1 | 2022 | 43 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 116 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 264 | 0.050 |
Why?
| | Sex Education | 1 | 2022 | 34 | 0.050 |
Why?
| | Hot Flashes | 1 | 2023 | 92 | 0.040 |
Why?
| | Contraceptive Agents | 1 | 2022 | 66 | 0.040 |
Why?
| | Psychometrics | 1 | 2026 | 731 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 365 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2026 | 1115 | 0.040 |
Why?
| | Iron | 1 | 2024 | 359 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2181 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2024 | 321 | 0.040 |
Why?
| | Nutritional Status | 1 | 2023 | 353 | 0.040 |
Why?
| | Biofilms | 2 | 2014 | 292 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2021 | 80 | 0.040 |
Why?
| | Attitude | 1 | 2022 | 259 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 309 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 900 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 178 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 326 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2026 | 956 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2022 | 1368 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 778 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 10 | 0.040 |
Why?
| | Ecosystem | 1 | 2023 | 478 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 610 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 172 | 0.030 |
Why?
| | British Columbia | 1 | 2018 | 25 | 0.030 |
Why?
| | Genetic Testing | 1 | 2021 | 483 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2602 | 0.030 |
Why?
| | trans-Golgi Network | 2 | 2007 | 15 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2016 | 3634 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2026 | 3416 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2024 | 736 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 392 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 162 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 322 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 42 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 4151 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 976 | 0.030 |
Why?
| | Leadership | 1 | 2020 | 402 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 193 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4556 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2023 | 1372 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 540 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 77 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1557 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 971 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1083 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1378 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2013 | 31 | 0.020 |
Why?
| | Cohort Studies | 1 | 2023 | 6032 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1547 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 337 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 198 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 354 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2823 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 28 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 217 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 451 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 404 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 388 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 557 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8346 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2123 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2007 | 80 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 480 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 23 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 2007 | 38 | 0.020 |
Why?
| | Epithelial Sodium Channels | 1 | 2007 | 21 | 0.020 |
Why?
| | Sodium | 1 | 2007 | 198 | 0.010 |
Why?
| | Purines | 1 | 2007 | 187 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 532 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1049 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 474 | 0.010 |
Why?
| | Mice | 2 | 2013 | 18355 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1399 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 892 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4568 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2191 | 0.010 |
Why?
| | Insulin | 1 | 2012 | 2516 | 0.010 |
Why?
| | Macrophages | 1 | 2007 | 1507 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 5223 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|